Tafasitamab - Incyte Corporation
Alternative Names: anti-CD19 MAb XmAb5574; anti-CD19 MoAb XmAb5574; ICP-B04; INCMOR0208; Minjuvi; Monjuvi; MOR 208; MOR-00208; Tafasitamab-cxix; XENP-5574; XmAb-5574Latest Information Update: 22 Aug 2024
At a glance
- Originator Xencor
- Developer Incyte Corporation; InnoCare Pharma; Knight Therapeutics; MorphoSys; Pfizer; University Medical Center of the Johannes Gutenberg University Mainz; Xencor
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diffuse large B cell lymphoma
- Phase III Follicular lymphoma; Marginal zone B-cell lymphoma
- Phase II B-cell lymphoma; Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 15 Aug 2024 Incyte announces intention to file a sBLA for tafasitamab for Follicular lymphoma by the end of the year
- 15 Aug 2024 Efficacy data from the phase III inMIND trial in Follicular Lymphoma released by Incyte
- 21 Jun 2024 MorphoSys completes a phase-II/III trial in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in USA, Portugal, Australia, Turkey, Romania, New Zealand, Poland, Italy, Germany, United Kingdom, Singapore, South Korea, Czech Republic, Canada, Israel, Taiwan, Serbia, Croatia, Spain, Finland, Austria and Hungary, France(IV) (NCT02763319)